

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the present application.

Listing of Claims:

1. **(Currently Amended)** A method for ~~prophylactic priming or curative treatment of the cervix and the myometrium for~~ establishing effective labor in women, comprising the step of:

administering to a pregnant woman an effective amount of at least one sulfated glycosaminoglycan selected from the group consisting of heparan sulfate, depolymerised heparan sulfate, dermatan sulfate, depolymerised dermatan sulfate, low molecular weight heparan and depolymerised heparan, said sulfated glycosaminoglycan having an anticoagulant activity of 100 BP units/mg or less to prophylactically prime or curatively treat the cervix and myometrium for the prevention or treatment of slow progress of term labor.

2. **(Previously Presented)** The method according to claim 1, wherein the at least one glycosaminoglycan comprises at least one glycosaminoglycan selected from the group consisting of heparan sulfate and depolymerised heparan sulfate.

3. **(Canceled)**

4. **(Previously Presented)** The method according to claim 1, wherein the at least one glycosaminoglycan comprises at least one glycosaminoglycan selected from the group consisting of dermatan sulfate and depolymerised dermatan sulfate.

5. **(Currently Amended)** The method according to claim 1, wherein the at least one glycosaminoglycan comprises depolymerised heparin heparan having an average molecular weight below 10 000 Da.

6. **(Currently Amended)** The method according to any one of ~~claims 1-5~~, claims 1, 2, 4 or 5, wherein the at least one glycosaminoglycan has an anticoagulant activity of 30 BP units/mg or less.

7. **(Canceled)**

8. **(Previously Presented)** The method according to claim 1, wherein the at least one glycosaminoglycan is administered in combination with oxytocin.

9. **(Previously Presented)** The method according to claim 1, wherein the at least one glycosaminoglycan is administered topically in a topical pharmaceutical preparation.

10. **(Previously Presented)** The method according to claim 1, wherein the at least one glycosaminoglycan is administered in a parenteral pharmaceutical preparation.

11. (**Currently Amended**) The method according to claim 5, wherein the at least one glycosaminoglycan comprises depolymerised heparin heparan having a molecular weight not higher than 6,000 Da.